|
2023 Conference Publication Factors that influence clinical trial participation for oncology patients in Australia: A scoping reviewYou, Kyung Ha, Lwin, Zarnie, Ahern, Elizabeth Stephanie, Roberts, Natasha Anne and Wyld, David (2023). Factors that influence clinical trial participation for oncology patients in Australia: A scoping review. 2023 ASCO Quality Care Symposium, Boston, MA United States, 27-28 October 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/op.2023.19.11_suppl.111 |
|
2023 Journal Article The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosisGuccione, Lisa, Gough, Karla, Drosdowsky, Allison, Price, Timothy, Pavlakis, Nick, Wyld, David, Ransom, David, Michael, Michael and Schofield, Penelope (2023). The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis. Supportive Care in Cancer, 31 (10) 577, 1-11. doi: 10.1007/s00520-023-08034-5 |
|
2023 Journal Article Exploring equity in cancer treatment, survivorship, and service utilisation for culturally and linguistically diverse migrant populations living in Queensland, Australia: a retrospective cohort studyScanlon, Brighid, Durham, Jo, Wyld, David, Roberts, Natasha and Toloo, Ghasem Sam (2023). Exploring equity in cancer treatment, survivorship, and service utilisation for culturally and linguistically diverse migrant populations living in Queensland, Australia: a retrospective cohort study. International Journal for Equity in Health, 22 (1) 175, 1-10. doi: 10.1186/s12939-023-01957-9 |
|
2023 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Tran, Ben, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Annual Meeting, Chicago, IL USA, 2-6 June 2023. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps5102 |
|
2023 Journal Article Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancerLee, Shu Fen, Brown, Teresa, Wyld, David, Edwards, Anna and Eastgate, Melissa (2023). Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer. Journal of Human Nutrition and Dietetics, 36 (3), 612-621. doi: 10.1111/jhn.13091 |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Ben Tran,, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Journal Article Rethinking cancer prevention for migrant populations in Queensland, Australia: A retrospective cohort study comparing culturally and linguistically diverse and Australian born cancer patientsScanlon, Brighid, Wyld, David, Roberts, Natasha, Durham, Jo and Toloo, Ghasem (Sam) (2023). Rethinking cancer prevention for migrant populations in Queensland, Australia: A retrospective cohort study comparing culturally and linguistically diverse and Australian born cancer patients. Global Public Health, 18 (1) 2202213, 1-13. doi: 10.1080/17441692.2023.2202213 |
|
2023 Journal Article Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT)Li, Minmin, Chan, David L., Tapia Rico, Gonzalo, Cehic, Gabrielle, Lawrence, Ben, Wyld, David, Pattison, David A., Kong, Grace, Hicks, Rodney, Michael, Michael, Kiberu, Andrew Ddembe, Lim, Jennifer, Clifton-Bligh, Roderick, Tsang, Venessa, Roach, Paul J., Leyden, John, Diakos, Connie I., Price, Timothy J. and Pavlakis, Nick (2023). Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT). Neuroendocrinology, 113 (3), 281-288. doi: 10.1159/000526848 |
|
2023 Conference Publication PRRT for control of hypoglycaemia and disease progression due to metastatic insulinomaPattison, D. A., Kong, G., Hofman, M. S., Akhurst, T., Ravi, Kumar A. S., Michael, M., Wyld, D., Burge, M., Chiang, C., Sachithanandan, N., Love, A. and Hicks, R. (2023). PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma. 20th Annual ENETs Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Electr Network, Mar 22-24, 2023. HOBOKEN: WILEY. |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps431 |
|
2023 Conference Publication P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Ben Tran,, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Journal Article Essential elements of optimal dietary and exercise referral practices for cancer survivors: expert consensus for medical and nursing health professionalsJoseph, Ria, Hart, Nicolas H., Bradford, Natalie, Wallen, Matthew P., Han, Chad Y., Pinkham, Elizabeth P., Hanley, Brigid, Lock, Gemma, Wyld, David, Wishart, Laurelie, Koczwara, Bogda, Chan, Alexandre, Agbejule, Oluwaseyifunmi Andi, Crichton, Megan, Teleni, Laisa, Holland, Justin J., Edmiston, Kelli, Naumann, Leonie, Brown, Teresa and Chan, Raymond J. (2023). Essential elements of optimal dietary and exercise referral practices for cancer survivors: expert consensus for medical and nursing health professionals. Supportive Care in Cancer, 31 (1) 46, 1-14. doi: 10.1007/s00520-022-07509-1 |
|
2022 Journal Article COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional surveyScanlon, Brighid, Wyld, David, Firman, Paul, Nakagaki, Midori, Durham, Jo, Kennedy, Glen, Moran, Paul, Smith, Michael, Button, Elise and Gavin, Nicole (2022). COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey. Australian Health Review, 47 (1), 110-118. doi: 10.1071/ah22142 |
|
2022 Conference Publication Essential elements of optimal dietary and exercise referral practices for cancer survivors: Expert consensus for medical and nursing health professionalsJoseph, Ria, Hart, Nicolas H., Bradford, Natalie, Wallen, Matthew P., Han, Chad Y., Pinkham, Elizabeth P., Hanley, Brigid, Lock, Gemma, Wyld, David, Wishart, Laurelie, Koczwara, Bogda, Chan, Alexandre, Agbejule, Oluwaseyifunmi Andi, Crichton, Megan, Teleni, Laisa, Holland, Justin J., Edmiston, Kelli, Naumann, Leonie, Brown, Teresa and Chan, Raymond J. (2022). Essential elements of optimal dietary and exercise referral practices for cancer survivors: Expert consensus for medical and nursing health professionals. HOBOKEN: WILEY. |
|
2022 Conference Publication P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew, Pashankar, Farzana, Ben Tran,, Mazhar, Danish, Huddart, Robert, Wheater, Matthew, Walpole, Euan, Dunwoodie, Elaine, Feldman, Darren, Birtle, Alison, Stevanovic, Amanda G., Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2022). P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Clinical Oncology Society of Australia (COSA) 49th Annual Scientific Meeting, Brisbane, QLD, Australia, 2-4 November 2022. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.13869 |
|
2022 Conference Publication Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian settingKim, Hansoo, Kulasegaran, Tivya, Eastgate, Melissa, Wyld, David, Burge, Matthew and Nalder, Mark (2022). Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting. HOBOKEN: WILEY. |
|
2022 Conference Publication Appendiceal neuroendocrine tumours in individuals under the age of 50 years: A population-based study from Queensland, AustraliaMoorhead, William, Youl, Philippa, Moore, Julie and Wyld, David (2022). Appendiceal neuroendocrine tumours in individuals under the age of 50 years: A population-based study from Queensland, Australia. HOBOKEN: WILEY. |
|
2022 Conference Publication Factors that influence cancer clinical trials participation in Australia: A scoping reviewYou, Kyung Ha (Kathy), Lwin, Zarnie, Ahern, Elizabeth, Wyld, David and Roberts, Natasha (2022). Factors that influence cancer clinical trials participation in Australia: A scoping review. HOBOKEN: WILEY. |
|
2022 Conference Publication Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: <SUP>177</SUP>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final resultsPavlakis, Nick, Ransom, David Turner, Wyld, David, Sjoquist, Katrin Marie, Wilson, Kate, Gebski, Val, Murray, James, Kiberu, Andrew Ddembe, Burge, Matthew E., Macdonald, William, Roach, Paul, Pattison, David A., Butler, Patrick, Price, Timothy Jay, Michael, Michael, Lawrence, Benjamin James, Bailey, Dale L., Leyden, Simone, Zalcberg, John Raymond and Turner, Harvey (2022). Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final results. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2022 Conference Publication Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumorsHoe, Hui Jing and Wyld, David (2022). Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
